BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 36894390)

  • 1. Treatment and outcomes of immune checkpoint inhibitors-associated colitis/diarrhea: A systematic review and meta-analysis.
    Ding M; Zhang X; Wang J; Gao F; Zheng X; Yuan J; Qi X
    Dig Liver Dis; 2023 Dec; 55(12):1621-1631. PubMed ID: 36894390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Bishay K; Tandon P; Bourassa-Blanchette S; Laurie SA; McCurdy JD
    Curr Oncol; 2020 Oct; 27(5):e486-e494. PubMed ID: 33173388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
    Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
    Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies.
    Tran AN; Wang M; Hundt M; Chugh R; Ohm J; Grimshaw A; Ciarleglio M; Hung KW; Proctor DD; Price CC; Laine L; Al-Bawardy B
    J Immunother; 2021 Oct; 44(8):325-334. PubMed ID: 34380976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis.
    Nielsen DL; Juhl CB; Chen IM; Kellermann L; Nielsen OH
    Cancer Treat Rev; 2022 Sep; 109():102440. PubMed ID: 35917654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
    Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
    Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Pan J; Liu Y; Guo X; Bai Z; Levi Sandri GB; Méndez-Sánchez N; Qi X
    Expert Opin Drug Saf; 2022 Oct; 21(10):1275-1287. PubMed ID: 36214583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma.
    Favara DM; Spain L; Au L; Clark J; Daniels E; Diem S; Chauhan D; Turajlic S; Powell N; Larkin JM; Yousaf N
    ESMO Open; 2020 Jul; 5(4):. PubMed ID: 32641348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
    Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
    Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections.
    Ma W; Gong Z; Abu-Sbeih H; Peng Y; Peng F; Zou F; Charabaty A; Okhuysen PC; McQuade JL; Altan M; Zhang HC; Thomas AS; Wang Y
    Am J Clin Oncol; 2021 Aug; 44(8):402-408. PubMed ID: 34107499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of colitis in immune checkpoint inhibitors and in chemotherapy/placebo for solid tumors: a systematic review and meta-analysis.
    Wei W; Ding Y; He J; Wu J
    Transl Cancer Res; 2020 Jul; 9(7):4173-4187. PubMed ID: 35117786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
    Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
    Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis.
    Balibegloo M; Nejadghaderi SA; Sadeghalvad M; Soleymanitabar A; Salehi Nezamabadi S; Saghazadeh A; Rezaei N
    Int Immunopharmacol; 2021 Jul; 96():107796. PubMed ID: 34162158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis.
    Tandon P; Bourassa-Blanchette S; Bishay K; Parlow S; Laurie SA; McCurdy JD
    J Immunother; 2018 Apr; 41(3):101-108. PubMed ID: 29401166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis.
    Wang DY; Ye F; Zhao S; Johnson DB
    Oncoimmunology; 2017; 6(10):e1344805. PubMed ID: 29123955
    [No Abstract]   [Full Text] [Related]  

  • 16. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson.
    Wang Y; Abu-Sbeih H; Mao E; Ali N; Ali FS; Qiao W; Lum P; Raju G; Shuttlesworth G; Stroehlein J; Diab A
    J Immunother Cancer; 2018 May; 6(1):37. PubMed ID: 29747688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
    Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
    Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colonoscopic evaluation of diarrhea/colitis occurring as an immune-related adverse event.
    Yamauchi Y; Arai M; Akizue N; Ohta Y; Okimoto K; Matsumura T; Fan MM; Imai C; Tawada A; Kato J; Kato N; Takiguchi Y
    Jpn J Clin Oncol; 2021 Mar; 51(3):363-370. PubMed ID: 33290513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors in advanced lung cancer: A systematic review and meta-analysis.
    Zheng Y; Dong H; Yu Y; Hu Z; Xue C; Zhang X; Cui H
    Int Immunopharmacol; 2023 Oct; 123():110785. PubMed ID: 37598630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High Cancers: A Systematic Review and Meta-analysis.
    Petrelli F; Ghidini M; Ghidini A; Tomasello G
    JAMA Oncol; 2020 Jul; 6(7):1068-1071. PubMed ID: 32407439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.